SCHEMBL6031092

SCHEMBL6031092

CCCCCCCCCCCC(=O)Nc1sc(CCCCCCC)cc1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.59
HSD17B10 Q99714 4/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
ALOX15 P16050 2/20 0.51
ALDH1A1 P00352 5/20 0.48
KDM4E B2RXH2 3/20 0.48
HPGD P15428 2/20 0.48
TSHR P16473 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
POLB P06746 1/20 0.44
GRIN2C Q14957 1/20 0.43
LMNA P02545 1/20 0.43
SOAT1 P35610 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6029958 0.83 RXFP1 (0.58) RXFP1HSD17B10CYP1A2CYP2C9ALOX15
SCHEMBL6030270 0.82 EPHX1 (0.50) RXFP1HSD17B10ALOX15ALDH1A1MEN1
SCHEMBL6030418 0.81 HSD17B10 (0.54) RXFP1HSD17B10ALDH1A1KDM4ESMN1; SMN2
SCHEMBL6031509 0.81 HSD17B10 (0.54) RXFP1HSD17B10CYP1A2ALDH1A1KDM4E
SCHEMBL6031638 0.81 HSD17B10 (0.54) RXFP1HSD17B10ALDH1A1KDM4ESMN1; SMN2
SCHEMBL6031060 0.81 HSD17B10 (0.54) RXFP1HSD17B10ALDH1A1KDM4ESMN1; SMN2
SCHEMBL6031411 0.81 HSD17B10 (0.54) RXFP1HSD17B10ALDH1A1KDM4ESMN1; SMN2
SCHEMBL6031306 0.81 HSD17B10 (0.54) RXFP1HSD17B10ALDH1A1KDM4ESMN1; SMN2
SCHEMBL6031439 0.81 HSD17B10 (0.54) RXFP1HSD17B10ALDH1A1KDM4ESMN1; SMN2
SCHEMBL6029587 0.81 HSD17B10 (0.54) RXFP1HSD17B10ALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
EP-1467978-A4 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2005-11-02 EP disclosed
EP-1467978-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-20 EP disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 US disclosed
WO-2003053944-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL RXFP1 612/4885HSD17B10 126/4885CYP1A2 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.